HideChilds = False
SystemName =
 

Bioverativ is proud to support the CDC Foundation to collaborate with the U.S. Centers for Disease Control and Prevention’s (CDC) Division of Blood Disorders in the development and operation of a longitudinal sickle cell disease health surveillance data

Collaborating to advance care

Sickle Cell Disease

Sickle cell disease is estimated to affect more than 100,000 Americans and more than 18 million people worldwide. As we work to advance new and innovative therapies for sickle cell disease, we are also committed to having a positive impact on people and families living with sickle cell disease by advancing access to the information and resources needed to receive high-quality care.  

We are proud to support the development and operation of a longitudinal data collection system for Americans living with sickle cell disease through a collaboration with the U.S. Centers for Disease Control and Prevention (CDC) Foundation, the CDC Division of Blood Disorders, public health officials, patient advocates, healthcare providers, and other pharmaceutical  industry partners.

Data from the Sickle Cell Disease Longitudinal Data Collection Program will provide states, healthcare provider networks, and pharmaceutical and insurance companies with information to allow for a better understanding of medical and educational interventions that improve sickle cell disease patient outcomes over time. The goals of the program are to ensure better, more cost-effective care for individuals and families affected by sickle cell disease and better data to inform healthcare providers.

Learn more about Bioverativ’s pipeline programs for sickle cell disease.